secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210291
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio Q1 net loss narrows to $19.6M; cash at $157M; KRRO-121 filing on track for H2 2026
--------------------------------------------------------------------------------

- Net loss of $19.6M vs $23.4M in Q1 2025; R&D spend down to $12.9M from $19.7M.
- Cash, equivalents and marketable securities $157.1M as of March 31 (up from $85.2M), extending runway into H2 2028.
- Closed oversubscribed $85M private placement led by Venrock Healthcare Capital Partners.
- KRRO-121 regulatory filing for UCD/HE on track for H2 2026; AATD GalNAc candidate expected Q2 2026.
- No collaboration revenue due to 12-month pause of Novo Nordisk partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526210291/0001193125-26-210291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526210291/krro-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer